Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Brodská, Petra; Schmid‐Grendelmeier, Peter

doi:10.1159/000346284

Cited by 39 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anafilaksi veya sistemik reaksiyon öyküsü bulunan hastalara epinefrin hazır enjektör gibi acil durum kitleri verilmelidir (6,12) . Alangari AA ve ark.…”

Section: Discussionunclassified

A rare cause of anaphylaxis; cold exposure

Topal¹,

Bahçeci²,

Karaman³

et al. 2018

BUCH

View full text Add to dashboard Cite

“…Anafilaksi veya sistemik reaksiyon öyküsü bulunan hastalara epinefrin hazır enjektör gibi acil durum kitleri verilmelidir (6,12) . Alangari AA ve ark.…”

Section: Discussionunclassified

A rare cause of anaphylaxis; cold exposure

Topal¹,

Bahçeci²,

Karaman³

et al. 2018

BUCH

View full text Add to dashboard Cite

“…Third‐line therapies include montelukast, ciclosporin or omalizumab. Recent case reports have indicated the efficacy of omalizumab also in HU at the same dose as recommended for idiopathic chronic urticaria …”

Section: Discussionmentioning

confidence: 99%

Heat urticaria: a revision of published cases with an update on classification and management

et al. 2016

View full text Add to dashboard Cite

Heat urticaria (HU) is a rare type of physical inducible urticaria, characterized by itchy erythema and well-demarcated weals appearing soon after heat exposure. Most cases occur in female patients aged 20-45 years. Both localized and generalized forms exist, depending on the limitation of the reaction to the skin area directly exposed to the physical stimulus or the involvement of distant sites, respectively. In most cases, HU is an immediate reaction, but delayed forms (mostly familial) have been described. HU is a long-lasting disease with overall duration at diagnosis of approximately 2 years. In about half of cases it is associated with systemic symptoms such as weakness, wheezing, headache, flushing, nausea, vomiting, diarrhoea, tachycardia, even dyspnoea or syncope. The main differential diagnosis includes cholinergic urticaria, exercise-induced anaphylaxis and solar urticaria. The diagnosis of HU is established by provocation testing, which is also helpful to evaluate the critical temperature threshold. The mean threshold temperature is about 44 °C. A heat desensitization programme can be an effective treatment. Nonsedating H1 antihistamines administered at licensed doses are the mainstay of symptomatic therapy in nearly 60% of patients, but full symptom relief is achieved in only a minority of them. Omalizumab has proven effective in recent case reports.

show abstract

“…While omalizumab has been shown to be effective in case reports, larger randomised controlled trials are needed to establish its effect 30 31…”

Section: Discussionmentioning

confidence: 99%

Cold-induced urticaria: challenges in diagnosis and management

Hochstadter

Ben‐Shoshan²

2013

BMJ Case Reports

View full text Add to dashboard Cite

SUMMARYCold-induced urticaria (CU) is a chronic physical urticaria that can be hard to diagnose and manage. Symptoms of CU can vary from mild localised urticaria, angio-oedema to anaphylaxis. CU may be induced by a wide range of cold triggers from aquatic activities to ingestions of cold substances. This exemplifies the importance of accurate diagnosis and management of patients with CU. We present three cases of CU that demonstrate the variability in triggers and clinical presentation. BACKGROUND

show abstract

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Cited by 39 publications

References 28 publications

A rare cause of anaphylaxis; cold exposure

A rare cause of anaphylaxis; cold exposure

Heat urticaria: a revision of published cases with an update on classification and management

Cold-induced urticaria: challenges in diagnosis and management

Contact Info

Product

Resources

About